Page 67 - Read Online

Page 14 of 15 Zanello et al. Rare Dis Orphan Drugs J 2023;2:9 https://dx.doi.org/10.20517/rdodj.2023.04

Transl Med 2021;13:eabd5524. DOI PubMed
8. Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov
2019;18:41-58. DOI PubMed
9. Member States, National Competent Authorities; EU Innovation Offices. Proposal for a framework to support not-for-profit
organisations and academia (institutions and individuals) in drug repurposing. Available from: https://ec.europa.eu/health/system/files/
2021-10/pharm773_repurposing_annex_en_0.pdf [Last accessed on 11 Apr 2023].
10. Miller KL, Lanthier M. Investigating the landscape of US orphan product approvals. Orphanet J Rare Dis 2018;13:183. DOI PubMed
PMC
11. U.S. Food and Drug Administration. Search orphan drug designations and approvals. Available from: https://www.accessdata.fda.gov/
scripts/opdlisting/oopd/ [Last accessed on 11 Apr 2023].
12. Orphanet Inserm US14. Lists of medicinal products for rare diseases in Europe. Available from: https://www.myobase.org/
doc_num.php?explnum_id=10705 [Last accessed on 11 Apr 2023].
13. Postema PG, Schwartz PJ, Arbelo E, et al. Continued misuse of orphan drug legislation: a life-threatening risk for mexiletine. Eur
Heart J 2020;41:614-7. DOI PubMed
14. Simoens S, Picavet E, Cassiman D, Dooms M. PHP15 What price do we pay for repurposing medicines for rare diseases? Value in
Health 2012;15:A15-6. DOI
15. WHO/EURO. Repurposing of medicines in oncology - the underrated champion of sustainable innovation. Available from: https://
apps.who.int/iris/bitstream/handle/10665/342567/WHO-EURO-2021-2807-42565-59178-eng.pdf?sequence=1&isAllowed=y [Last
accessed on 11 Apr 2023].
16. Aartsma-Rus A, Vroom E, O’Reilly D. The role of patient involvement when developing therapies. Nucleic Acid Ther 2022;32:118-22.
DOI PubMed PMC
17. Cavaller-Bellaubi M, Faulkner SD, Teixeira B, et al. Sustaining meaningful patient engagement across the lifecycle of medicines: a
roadmap for action. Ther Innov Regul Sci 2021;55:936-53. DOI PubMed PMC
18. Hoos A, Anderson J, Boutin M, et al. Partnering with patients in the development and lifecycle of medicines: a call for action. Ther
Innov Regul Sci 2015;49:929-39. DOI PubMed PMC
19. REPO4EU. The Euro-global platform for mechanism-based drug repurposing. Available from: https://repo4.eu/ [Last accessed on 11
Apr 2023].
20. REMEDi4ALL. The European Platform for medicines repurposing. Available from: https://remedi4all.org/ [Last accessed on 11 Apr
2023].
21. European Commission. Horizon Europe work programme 2021-2022. Available from: https://ec.europa.eu/info/funding-tenders/
opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-4-health_horizon-2021-2022_en.pdf [Last accessed on 11 Apr 2023].
22. U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER).
Guidance for industry applications covered by section 505(b)(2). Available from: https://www.fda.gov/media/72419/download [Last
accessed on 11 Apr 2023].
23. Hechtelt Jonker A, Hivert V, Gabaldo M, et al. Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development
Guidebook. Nat Rev Drug Discov 2020;19:495-6. DOI PubMed
24. IRDIRC. Drug Repurposing guidebook. Available from: https://irdirc.org/drug-repurposing-guidebook/ [Last accessed on 11 Apr
2023].
25. Asker-Hagelberg C, Boran T, Bouygues C, et al. Repurposing of medicines in the EU: launch of a pilot framework. Front Med
(Lausanne) 2021;8:817663. DOI PubMed PMC
26. Hivert V, Jonker AH, O’connor D, Ardigo D. IRDiRC: 1000 new rare diseases treatments by 2027, identifying and bringing forward
strategic actions. Rare Dis Orphan Drugs J 2022;1:3. DOI
27. National Institute of Allergy and Infectious Diseases (NIAID). NOT-AI-16-052: Notice of NIAID’s participation in PA-16-183
“limited competition: Rare Diseases Clinical Research Network (RDCRN) Project supplements for clinical trials to repurpose drugs in
collaboration with e-rare awardees (Admin Supp)”. Available from: https://grants.nih.gov/grants/guide/notice-files/NOT-AI-16-
052.html [Last accessed on 11 Apr 2023].
28. National Center for Advancing Translational Sciences (NCATS). NOT-TR-19-029: NCATS announces the cures acceleration network
review board workshop: repurposing off-patent drugs: research & regulatory challenges. Available from: https://grants.nih.gov/grants/
guide/notice-files/NOT-TR-19-029.html [Last accessed on 11 Apr 2023].
29. ERA-LEARN. E-Rare 3 call for proposals 2016 (JTC 2016): clinical research for new therapeutic uses of already existing molecules
(repurposing) in rare diseases. Available from: https://www.era-learn.eu/network-information/networks/e-rare-3/e-rare-3-call-for-
proposals-2016-jtc-2016-clinical-research-for-new-therapeutic-uses-of-already-existing-molecules-repurposing-in-rare-diseases [Last
accessed on 11 Apr 2023].
30. European Medicines Agency. Clinical trials regulation. Available from: https://www.ema.europa.eu/en/human-regulatory/research-
development/clinical-trials/clinical-trials-regulation [Last accessed on 11 Apr 2023].
31. PARADIGM. Patient engagement toolbox. Available from: https://imi-paradigm.eu/petoolbox/ [Last accessed on 11 Apr 2023].
32. U.S. Food Drug Administration. Repurposing off-patent drugs: research & regulatory challenges. Available from: https://
www.fda.gov/drugs/news-events-human-drugs/repurposing-patent-drugs-research-regulatory-challenges-12052019-12062019 [Last
accessed on 11 Apr 2023].